Newsroom | 90899 results

HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biopharmaceutical company pioneering next-generation dual-payload antibody-drug conjugates (ADCs) that have the potential to deliver safer more durable responses in patients, including those resistant to approved ADC therapies, today announced that it has been named the Winner of “Best Drug Developer” at the 2025 World ADC Awards. CrossBridge Bio was selected from a competitive global field by a panel of independent ADC experts and peers. The award r...

EDMONTON, AB--(BUSINESS WIRE)--The Canadian Union of Public Employees Alberta Division (CUPE Alberta) has launched a website and advertising campaign asking the province’s conservative government to “axe the tax” on COVID vaccines. CUPE has launched a website at www.axethevaxtax.ca, which allows Albertans to send a letter to Premier Danielle Smith, NDP leader Naheed Nenshi, and their local MLA protesting the $100 fee charged to Albertans getting a COVID vaccination. CUPE is also advertising on...

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today presented promising new Phase 2 data from its ongoing study of imneskibart in patients with checkpoint inhibitor (CPI)-refractory melanoma and non-small cell lung cancer (NSCLC). The data were shared in a poster session at the Society for Immunotherapy of Cancer (SITC) 40th Annual M...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in hypereosinophilic syndrome (HES),1 a rare disease driven by elevated eosinophils.2 These data will be presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, Florida. Hypereosinophilic Syndrome (HES) is a group of...

HOUSTON & SEATTLE--(BUSINESS WIRE)--Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today announced the presentation of data highlighting the clinical activity of IDP-023, the Company’s allogeneic g-NK cell therapy, in patients with relapsed/refractory multiple myeloma. IDP-023 treatment was given as a standalone therapy and in combination with isatuxi...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days....

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced positive initial results from a Phase 1a/1b clinical trial of STK-012 in first-line, PD-L1 negative nonsquamous (NSQ) non-small cell lung cancer (NSCLC) in combination with standard of care (SoC) pembrolizumab and chemotherapy (PCT). The data will be presented by Adam J. Schoenfeld, M.D., Memorial Sloan Kettering Cancer Center, New York, as a late-breaking oral presentation at the...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK) published results from the Phase III HARMONi-A trial, conducted in China and sponsored by Akeso, featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as part of the Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) in National Harbor, M...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1 criteria. Overall survival is a key secondary endpoi...

SAN DIEGO--(BUSINESS WIRE)--Scientist.com, la plataforma líder de coordinación de I+D con IA para las ciencias de la vida, ha sido galardonada con el premio a la excelencia en la gestión de los proveedores por los prestigiosos premios B2B Ecommerce Awards. Se trata de un galardón que reconoce a las organizaciones que sientan nuevos parámetros en materia de innovación, integración y rendimiento de la red de proveedores para ofrecerle un valor superior al cliente. "Haber ganado este premio es un...